Results for "The Role of Distributors in the U.S. Specialty Pharmaceuticals Value Chain"
HDA Distributors Proud to Partner With Pharmacists Each Step of the Way
October marks American Pharmacists Month, an important opportunity to recognize the profound contribution of dedicated pharmacists who work on the frontlines of U.S. healthcare on a daily basis.
Transitioning COVID-19 Product Distribution to the Commercial Market
Throughout the COVID-19 pandemic, the federal government has primarily coordinated response efforts with the support of the private sector to develop, produce and distribute vaccines, personal protective equipment (PPE) and therapeutics. While this public health crisis continues, government and private-sector stakeholders are already thinking about the expected transition of COVID-19 product distribution to the commercial market — which could happen as early as the first quarter of this year.
COVID-19 Reinforces KeySource’s Commitment to Helping Those in Need
Since 2006, thousands of uninsured and underinsured patients in Cincinnati, Ohio, and neighboring communities have been able to fill their critically needed medications at no charge through the St. Vincent de Paul Charitable Pharmacy. By filling prescriptions with no out-of-pocket cost for patients, the charitable pharmacy is committed to providing care for individuals who need it most.
HDA’s Davis Shares 2022 Strategic Priorities Under Increased Awareness of Supply Chains
Events spanning COVID-19 vaccine distribution to shipping containers held up at port have made the supply chain a “kitchen-table” issue during the past year. Many industries experienced notable disruptions in their delivery of goods and supplies; however, as noted by President and CEO Chip Davis, “[P]harmacies, health systems and physicians’ offices, more than 180,000 across the country, remain stocked with the lifesaving medications and vaccines patients need. That didn’t happen by accident.” Davis’ perspective was featured alongside healthcare supply chain association leaders as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.